MAD2L1BP抗体 新品

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane 1-4: A549 cells, 231 cells, PC3 cells, hela cells, Primary antibody: P07431(MAD2L1BP Antibody) at dilution 1/675, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P07431(MAD2L1BP Antibody) at dilution 1/65. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P07431(MAD2L1BP Antibody) at dilution 1/65. (Original magnification: ×200)    

  
  

The MAD2L1BP (MAD2L1 Binding Protein) antibody is a tool used to study the MAD2L1BP protein, also known as p31comet, which plays a critical role in regulating the spindle assembly checkpoint (SAC) during mitosis. MAD2L1BP interacts directly with MAD2 (Mitotic Arrest Deficient 2), a key component of the SAC that ensures proper chromosome segregation by delaying anaphase until all chromosomes are correctly attached to spindle microtubules. By binding to MAD2. MAD2L1BP facilitates the inactivation of the SAC, promoting the transition from metaphase to anaphase and ensuring timely mitotic exit. This dynamic interaction is essential for maintaining genomic stability and preventing aneuploidy, a hallmark of many cancers.

Research using MAD2L1BP antibodies has elucidated its dual role in both checkpoint silencing and cancer progression. Overexpression or dysregulation of MAD2L1BP is linked to checkpoint override, chromosomal instability, and tumorigenesis. The antibody is widely employed in techniques such as Western blotting, immunofluorescence, and immunohistochemistry to detect protein expression levels, subcellular localization, and interactions in various cellular and tissue contexts. It has become indispensable for studying cell cycle regulation, mitotic errors, and mechanisms underlying cancer development. Additionally, its utility extends to drug discovery, where it helps evaluate compounds targeting the SAC for cancer therapy. Understanding MAD2L1BP's function through antibody-based assays continues to provide insights into mitotic control pathways and potential therapeutic interventions.